The Latest Cardiac and Vascular News
GE Healthcare, Medtronic receive FDA 510(k) clearance and CE Mark approval on the integration of advanced INVOS™ regional oximetry and Microstream™ capnography technologies on the CARESCAPE precision monitoring platform Helping providers improve patient outcomes and safety, Microstream™ capnography (CO2) technology captures evolving respiratory compromise while INVOS™ regional oximetry (rSO2) technology […]
Built on the market-leading IN.PACT™ Admiral™ DCB technology, the IN.PACT™ 018 DCB is engineered to cross tight lesions and designed for better deliverability§ Medtronic today announced approval from the U.S. Food and Drug Administration (FDA) for the IN.PACT™ 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, a drug coated balloon […]
Mid-single digit FY22 revenue growth; Q4 results affected by temporary global supply chain impacts and China lockdowns DUBLIN, May 26, 2022 /PRNewswire/ — Medtronic plc (NYSE: MDT) today announced financial results for its fourth quarter and fiscal year 2022, which ended April 29, 2022. Key Highlights FY22 revenue increased 5% reported and organic FY22 GAAP diluted […]
Medtronic adds to SPYRAL HTN Global Clinical Program with late breaking clinical data for SPYRAL HTN-ON MED and GSR-DEFINE DUBLIN and PARIS, May 17, 2022 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced data showing the benefits of the Symplicity Blood Pressure Procedure with the Symplicity Spyral™ Renal Denervation […]
The Onyx Frontier™ drug-eluting stent offers an innovative delivery system and builds upon the acute performance and clinical data from the Resolute Onyx™ drug-eluting stent DUBLIN, May 13, 2022 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received U.S. Food and Drug Administration (FDA) approval for the Onyx […]
EXPAND TAVR II Pivotal Trial evaluating the Evolut™ TAVR platform in a new patient population Medtronic today announced the first patient enrollment in the EXPAND TAVR II Pivotal Trial, the first randomized clinical trial evaluating the self-expanding, supra-annular Evolut™ TAVR platform in patients with moderate, symptomatic aortic stenosis (AS), a […]
Dr. Laura Mauri will drive integration of medical and scientific intelligence and patient safety and engagement as chief scientific, medical and regulatory officer DUBLIN, April 25, 2022 /PRNewswire/ — Medtronic plc (NYSE:MDT) today announced that Laura Mauri, M.D., M.S.c. has been appointed Medtronic Chief Scientific, Medical and Regulatory Officer. This appointment adds to Dr. Mauri’s […]
Medtronic adds to its robust clinical program with long-term data demonstrating the continued blood pressure lowering effect of the Symplicity renal denervation procedure Medtronic also completes enrollment in the SPYRAL HTN-ON MED trial DUBLIN and WASHINGTON, April 4, 2022 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced long-term data […]
ACC.22: Late-breaking data show CoreValveTM and EvolutTM is the only platform to out-perform surgery in valve durability at five years Medtronic today unveiled new insights from a pooled analysis of high and intermediate risk patients from the CoreValve/Evolut program, showing a lower occurrence in structural valve deterioration (SVD) in patients […]
Company advanced its pipeline, launched new products, won share, and delivered earnings growth despite COVID-19 impact on healthcare procedure volumes DUBLIN, Feb. 22, 2022 /PRNewswire/ — Medtronic plc (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2022, which ended January 28, 2022. Key Highlights Revenue of $7.8 billion was flat year-over-year […]
